UPDATE: Alexion Pharma (ALXN) Reports Q2 Revenue of $753M; Trims FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Reports Second Quarter 2016 Results
July 28, 2016 6:30 AM EDT- Total Revenues of $753 Million; Increased 18 Percent Year-on-Year; 23 Percent Volume Increase Year-on-Year-
- Soliris® (eculizumab) Revenue Growth Driven by Steady Number of New Patients with PNH and aHUS Treated Globally -
- Strong Strensiq® (asfotase alfa) Launch Continues in Initial Countries -
- Kanuma® (sebelipase alfa) Launch Progresses with Newly Identified Patients Starting on Treatment -
- Eculizumab Phase 3 REGAIN Data in Refractory gMG Presented at the ICNMD Congress -
- ALXN1210 Phase 1/2 Data Showed Rapid and Sustained Reductions in LDH in All... More
